Omaha, Neb (May 7, 2026) – CQuence Health is excited to welcome Grasshopper Health to its portfolio of innovative healthcare companies.
Grasshopper Health, led by founder and CEO Richard Vlasimky, is using continuous gait monitoring to enable earlier disease insights, more precise monitoring and longer, healthier independence.
“Gait speed is one of the most well-studied indicators associated with long-term health outcomes,” said Vlasimsky. “Even if I knew your BMI, research shows gait speed correlates more strongly with five-year outcomes than many traditional measures.”
For decades, clinicians worldwide have relied on five vital signs to understand our health: blood pressure, heart rate, temperature, respiration and weight.
But one critical indicator is missing: gait.
Studies led by researchers at the University of Nebraska at Omaha revealed that quiet changes in gait could signal early neurological, vascular and cognitive decline, often years before disease symptoms actually appear. Their work became the first published evidence that gait changes were associated with peripheral artery disease, even before symptom onset.
That insight sparked the creation of Grasshopper Health.
The company is currently focused on measuring and monitoring early insights for Alzheimer’s, Parkinson’s, Normal Pressure Hydrocephalus and Peripheral Artery Disease. However, they hope to expand into more conditions, as it’s estimated that more than 20 diseases have known gait associations. They are also interested in supporting fields like sports medicine and physical therapy.
To capture data, Grasshopper pairs wearable technology with a patient’s smartphone to monitor movement in real time. The Axis PatchTM* is a lightweight, discreet wearable placed at the sacrum, the body’s biomechanical fulcrum. This unique positioning helps to surface subtle gait patterns invisible to the human eye.
For patients, the experience is seamless: no behavior change, lab visits, technical setup or disruptions to daily life. Continuous monitoring happens passively in the background, making it easy to participate without added burden.
For clinicians, this approach delivers objective, real-world data via Grasshopper Health’s mobile app and AI platform, enabling care teams to monitor patients remotely and respond earlier when meaningful changes occur.
“What Grasshopper Health has built makes it possible to understand a person’s health in a way we’ve never been able to before,” said Kyle Salem, PhD, CEO of CQuence Health. “A small patch capturing real‑world gait data can open the door to better decision‑making for clinicians and, ultimately, lead to better outcomes for patients. That’s the kind of practical, meaningful innovation we’re committed to standing behind at CQuence Health, and we’re excited to help them take next steps.”
CQuence Health has invested in Grasshopper Health and will provide professional services to support its next phase of growth.
“The future of care depends on smarter monitoring, actionable insights and technologies that meet patients where they are. Grasshopper Health delivers all three,” said Chad Brough, VP of Growth at CQuence Health. “We’re excited to help accelerate this innovation and expand its impact across the continuum of care.”
The strategic partnership gives the company the support and direction it needs to advance its technology and move toward broader clinical adoption.
To learn more about Grasshopper Health, visit https://grasshopperhealth.com/
*The Axis PatchTM is currently intended for research use only.